Supreme Court divided on Roundup litigation, hinting at uncertain future for mass cancer lawsuits

The United States Supreme Court convened to consider a petition challenging a lower‑court ruling that held the manufacturer of the popular glyphosate‑based herbicide liable for allegedly causing cancer, a proceeding that quickly revealed a noticeable fissure among the nine justices, with at least three expressing skepticism toward the plaintiffs’ scientific claims while a similar number appeared inclined to preserve the avenue for thousands of pending lawsuits, leaving the remaining members ostensibly undecided and thereby rendering the Court’s stance ostensibly ambiguous.

During oral arguments, the petitioners emphasized decades‑old epidemiological studies that the majority of regulatory agencies have deemed insufficient to establish causation, a point that elicited a probing question from a justice concerned about the precedent of allowing speculative injury claims to undermine corporate accountability, whereas the respondents invoked the substantial settlement history and the emergent consensus among independent researchers that glyphosate may indeed pose carcinogenic risks, a line of reasoning that prompted another justice to underscore the Court’s historical reluctance to intervene in complex scientific disputes without a clear statutory directive.

Following the session, the Court’s internal voting reportedly split along ideological lines, an arrangement that, while not unprecedented, underscores a procedural inconsistency whereby the same institution tasked with delivering uniform legal interpretation now appears to perpetuate a predictable stalemate that may effectively deny resolution to plaintiffs seeking redress, thereby exposing a systemic gap between the judiciary’s professed role as an arbiter of justice and its practical capacity to adjudicate large‑scale public health litigation in a timely and coherent manner.

In the broader context, the apparent division signals to litigants, corporations, and regulators alike that the Supreme Court remains hesitant to deliver a decisive watershed ruling that could either open the floodgates for further cancer‑related claims or, conversely, close them definitively, a hesitation that reflects an institutional inertia that, while perhaps intended to preserve judicial prudence, inevitably leaves thousands of affected individuals in a prolonged state of legal uncertainty and highlights the paradox of a supreme institution whose procedural deliberations often eclipse the substantive urgency of the underlying public health concerns.

Published: April 28, 2026